Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 11:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 565 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: IMRT Clear all
Completed Not applicable Interventional

High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Radiation Therapy for Prostate Cancer

NCT00243321
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
high dose-rate brachytherapy, intensity-modulated radiation therapy
Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 18, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer

NCT00713219
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
IMRT, cetuximab, docetaxel
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
6
States / cities
Omaha, Nebraska • Basking Ridge, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Oct 18, 2026, 11:47 AM EDT
Completed Phase 1 Interventional

sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC

NCT04091867
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
sEphB4-HSA with chemotherapy, Cetuximab, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 18, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Results available

Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

NCT02427841
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Interventions
Fluorouracil, Gemcitabine, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Nab-paclitaxel, Therapeutic Conventional Surgery
Drug · Radiation · Other + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 18, 2026, 11:47 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies

NCT00544466
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
fludarabine phosphate, melphalan, allogeneic hematopoietic stem cell transplantation, intensity-modulated radiation therapy
Drug · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
7 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 18, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Results available

A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients

NCT01661088
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
FOLFIRINOX, Intensity-modulated radiotherapy (IMRT), Surgical Exploration
Drug · Radiation · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 18, 2026, 11:47 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer

NCT00321698
View directory record Official record
Conditions
Prostate Cancer
Interventions
Intensity-Modulated Radiation Therapy (IMRT), Docetaxel+IMRT
Radiation · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2023
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 18, 2026, 11:47 AM EDT
Active, not recruiting Phase 3 Interventional

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

NCT00978458
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neurotoxicity
Interventions
temozolomide, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
168
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 117 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 18, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Results available

Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma

NCT00895622
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
54 Gy radiotherapy, 60 Gy radiotherapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
74
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 18, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Results available

Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions

NCT02086578
View directory record Official record
Conditions
Breast Cancer
Interventions
Breast MRI, Breast-Q© questionnaire, Multi-Beam IMRT
Device · Behavioral · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 18, 2026, 11:47 AM EDT
Suspended Phase 1 Interventional

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

NCT03975231
View directory record Official record
Conditions
BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma
Interventions
Dabrafenib, Intensity-Modulated Radiation Therapy, Trametinib
Drug · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Duarte, California • Columbus, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 18, 2026, 11:47 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

NCT03765918
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Pembrolizumab 200 mg, Radiotherapy 60 Gray, Radiotherapy 66 Gray, Radiotherapy 70 Gray, Cisplatin 100 mg/m^2
Biological · Radiation · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
68
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 18, 2026, 11:47 AM EDT
Not listed Phase 2 Interventional Results available

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

NCT00492778
View directory record Official record
Conditions
Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Endometrial Mucinous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Cancer
Interventions
3-Dimensional Conformal Radiation Therapy, Cisplatin, Intensity-Modulated Radiation Therapy, Internal Radiation Therapy
Radiation · Drug
Lead sponsor
GOG Foundation
Network
Eligibility
Female only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
439
States / cities
Auburn, California • Berkeley, California • Burbank, California + 292 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 18, 2026, 11:47 AM EDT
Completed Phase 2Phase 3 Interventional Results available

FACBC Outcomes for Post Prostatectomy

NCT01666808
View directory record Official record
Conditions
Prostate Cancer
Interventions
FACBC, Radiation therapy
Drug · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years · Male only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 18, 2026, 11:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer

NCT02990468
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
BMX-001, Radiation Therapy, Cisplatin
Drug · Radiation
Lead sponsor
BioMimetix JV, LLC
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
San Francisco, California • Gainesville, Florida • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 18, 2026, 11:47 AM EDT
Completed Phase 1Phase 2 Interventional

Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Prostate Cancer

NCT00653757
View directory record Official record
Conditions
Prostate Cancer
Interventions
goserelin acetate, leuprolide acetate, image-guided radiation therapy, intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
19 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 18, 2026, 11:47 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Uterine Serous Carcinoma and Adjuvant Combined Intraperitoneal Chemotherapy and Radiation

NCT04030000
View directory record Official record
Conditions
Uterine Carcinoma
Interventions
Paclitaxel/Carboplatin, Pelvic radiation therapy
Drug · Radiation
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 99 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 18, 2026, 11:47 AM EDT
Withdrawn Phase 2 Interventional

Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma

NCT00725400
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Cetuximab and Radiation Therapy, Surgery and Radiation Therapy
Other · Procedure
Lead sponsor
American Scitech International
Other
Eligibility
40 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Englishtown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 18, 2026, 11:47 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

NCT03137771
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
3-Dimensional Conformal Radiation Therapy (3D-CRT), Docetaxel, Gemcitabine, Intensity-Modulated Radiation Therapy (IMRT), Pemetrexed Disodium, Stereotactic Body Radiation Therapy (SBRT), Erlotinib Hydrochloride, Pembrolizumab
Radiation · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
296
States / cities
Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 228 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 18, 2026, 11:47 AM EDT
Completed Phase 1 Interventional

Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer

NCT02270606
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Rectum, Rectal Adenocarcinoma, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
intensity-modulated radiation therapy, fluorouracil, oxaliplatin, leucovorin calcium, therapeutic conventional surgery
Radiation · Drug · Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 18, 2026, 11:47 AM EDT
Completed Early Phase 1 Interventional

Single-Photon Emission Computed Tomography, Computed Tomography Lymphoscintigraphy, and Intensity-Modulated Radiation Therapy in Treating Patients Who Have Undergone Surgery for Stage I or Stage II Breast Cancer

NCT00743314
View directory record Official record
Conditions
Breast Cancer, Lymphedema
Interventions
screening questionnaire administration, computed tomography, lymphoscintigraphy, single photon emission computed tomography, intensity-modulated radiation therapy, technetium Tc 99m sulfur colloid
Other · Procedure · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 18, 2026, 11:47 AM EDT
Terminated Phase 1 Interventional

Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

NCT00800150
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
fludarabine phosphate, melphalan, nonmyeloablative allogeneic hematopoietic stem cell transplantation, intensity-modulated radiation therapy, tomotherapy, total marrow irradiation, total nodal irradiation
Drug · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
16 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 18, 2026, 11:47 AM EDT
Active, not recruiting Phase 2 Interventional

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

NCT04716946
View directory record Official record
Conditions
NSCLC, Non-small Cell Lung Cancer, Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IIIA, PD-L1 Gene Mutation
Interventions
Durvalumab, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
8
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 18, 2026, 11:47 AM EDT
Withdrawn Phase 2 Interventional

Stereotactic Body Radiotherapy (SBRT) With Concurrent Boost for Low- and Intermediate-Risk Prostate Cancer

NCT01409473
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate SBRT with concurrent boost to intraprostatic lesion(s)
Radiation
Lead sponsor
Rocky Mountain Cancer Centers
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • Littleton, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Oct 18, 2026, 11:47 AM EDT